PURPOSE:Genetically-targeted therapies are both promising and costly advances in the field of oncology. Several treatments for metastatic melanoma with a mutation in the BRAF gene have been approved. They extend life but are more expensive than the previous standard of care (dacarbazine). https://www.chiggate.com/majirel-majicontrast-red-rouge-for-sale/